Articles related to MULTIPLE SCLEROSIS (MS)

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

This innovative AI model, presented at the 2023 AACC Annual Scientific Meeting, demonstrates the potential to identify MS risk years in advance, offering a new horizon in early detection and patient care. Explore the full findings to understand how this could impact your practice.

This study underscores the association between a quality diet and reduced specific brain lesions in MS patients, without finding a connection to relapses or disability progression.

This comprehensive study reveals a significant immune response to cow milk proteins in MS patients, likely due to similarities with CNS proteins. The findings call for personalized dietary considerations and further research into the potential impact of various milk types on MS.

Gadoquatrane, a promising GBCA, enters Phase 3 clinical testing, potentially offering safer MRI procedures and advancing diagnostic capabilities for patients with CNS disorders, including MS.

Pioneering studies with clemastine, an over-the-counter antihistamine, are exhibiting groundbreaking findings in the repair of myelin, a protective coating on nerve fibers damaged in multiple sclerosis, based on ReBUILD clinical trial’s MRI data.